Everything below concerns freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
== F == FCS – Fluorescence correlation spectroscopy FCCS – Fluorescence cross-correlation spectroscopy FEM – Field emission microscopy FIB – Focused ion beam microscopy FIM-AP – Field ion microscopy–atom probe Flow birefringence Fluorescence anisotropy FLIM – Fluorescence lifetime imaging Fluorescence microscopy FOSPM – Feature-oriented scanning probe microscopy FRET – Fluorescence resonance energy transfer FRS – Forward Recoil Spectrometry, a synonym of ERD FTICR or FT-MS – Fourier-transform ion cyclotron resonance or Fourier-transform mass spectrometry FTIR – Fourier-transform infrared spectroscopy
The absorption rate constant Ka is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time−1. The Ka is related to the absorption half-life (t1/2a) per the following equation: Ka = ln(2) / t1/2a. Ka values can typically only be found in research articles. This is in contrast to parameters like bioavailability and elimination half-life, which can often be found in drug and pharmacology handbooks.
=== Metabolic activity === Several studies have investigated didymin's potential in metabolic disorders. In high-fat diet mouse models, didymin reduced postprandial blood glucose levels and improved insulin secretion by enhancing mitochondrial biogenesis and function in pancreatic beta cells. In a separate study, didymin alleviated metabolic dysfunction-associated fatty liver disease (MAFLD) in mice by activating Sirt1, thereby stimulating lipophagy and mitochondrial biogenesis. In insulin-resistant HepG2 cells, didymin enhanced glucose uptake and activated insulin receptor substrate-1, PI3K, Akt, and glycogen synthase kinase-3 (GSK-3), while inhibiting key enzymes of gluconeogenesis.
Sources: en.wikipedia.org
Since this series was only discovered and studied in 1947–1948, its nuclides were never given historic names. Each of the other series have many of their nuclides given historical names. This series has an isotope of radon only produced in a rare branch (not shown in the illustration) but not in the main decay sequence. Other series produce radon in the main decay sequence, which, if occurring in mineral, would tend to migrate through the mineral and be released as radioactive gas. This series ends in thallium (or, practically speaking, bismuth) rather than lead. Its parent nuclides are essentially extinct, explaining why the series was discovered much later, after the development of artificial nucleosynthesis. Each of the other series have primordial parent nuclides. The total energy released from neptunium-237 to thallium-205, including the energy lost to neutrinos, is 49.29 MeV; from californium-249, 66.87 MeV. As the energy of the final step from bismuth to thallium, though known, will not be available until the inconceivable future, it may be better to quote the figures 46.16 MeV and 63.73 MeV to bismuth-209.
, which may allow to redefine the distributions as simple functions of the age only. If the flow is steady (but a generalization to non-steady flow is possible) and is conservative, then the exit age distribution and the internal age distribution can be related one to the other:
Steiner believed that nationalism is too inherently violent to satisfy the moral prerogative of Judaism, having said "that because of what we are, there are things we can't do " and has suggested that Nazism was Europe's revenge on the Jews for inventing conscience; father of David Steiner (academic); executive director of the Johns Hopkins Institute for Education Policy; appointed to the Practitioner Council at the Hoover Institute, Stanford University. Hillel Steiner (born 1942) is a prolific author, scholar, academic, editor and political philosopher and is Emeritus Professor of Political Philosophy at the University of Manchester; signatory to the Euston Manifesto and elected to the Fellowship of the British Academy in 1999. He is a member of the following organisations: American Philosophical Association, Aristotelian Society, International Association for the Philosophy of Law and Social Philosophy, Basic Income Earth Network. British Philosophical Association, European Society for the History of Economic Thought, Political Studies Association, Society for Applied Philosophy, and the September Group.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.